South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
SCHAUMBURG, Ill., Feb. 03, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced that it will release financial results for the 2015 fourth quarter and full year pre-market on Tuesday, February 16, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Interested parties may access the live call by dialing:
Within the United States: 877-293-5456
International: 707-287-9357
A live webcast of the teleconference will be available on the company's website at: http://investor.sagentpharma.com/events.cfm.
A replay of the presentation will be available on the Sagent website or by dialing:
Toll-Free: 855-859-2056
Passcode: 45341464
The replay will be available until February 29, 2016.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a global specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 [email protected]
